Inclusion Criteria:

          -  Participant has confirmation of acute myeloid leukemia (AML) by World Health
             Organization (WHO) criteria.

          -  Participant is deemed by the investigator to be an appropriate candidate for
             outpatient ramp-up of venetoclax.

          -  Participant is not eligible to receive treatment with standard cytarabine and
             anthracycline induction regimens.

          -  Participant has not received prior treatment for AML (treatment naïve) with the
             exception of hydroxyurea.

          -  Participant has no evidence of spontaneous tumor lysis syndrome (TLS) at Screening.

          -  Participant can have progressed from myelodysplastic syndrome (MDS) or be considered
             to have secondary AML and could have been treated with growth factors or other agents
             with the exception of hypomethylating agents.

          -  Participant has adequate kidney, liver and hematology laboratory values as detailed in
             the protocol.

          -  Has an Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 3.

        Exclusion Criteria:

        - Has a history of the following conditions:

          -  Acute promyelocytic leukemia

          -  Known active central nervous system involvement with AML

          -  Positive for HIV (HIV testing is not required)

          -  Positive for hepatitis B or C infection with the exception of those with an
             undetectable viral load within 3 months

          -  Cardiovascular disability status of New York Heart Association Class > 2

          -  Chronic respiratory disease that requires continuous oxygen or any other medical
             condition that in the opinion of the investigator would adversely affect his/her
             participating in this study

          -  Malabsorption syndrome or other condition that precludes enteral route of
             administration

        Has a history of other malignancies within 2 years prior to study entry, with the exception
        of:

          -  Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of
             breast

          -  Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin

          -  Previous malignancy confined and surgically resected (or treated with other
             modalities) with curative intent